drugset
drugset / Trial / NCT02801903

Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris

NCT02801903 ↗

Phase 1 Completed 18 enrolled Novan, Inc. WCCT Global · collab
NaSingle-groupOpen-labelTreatment

Summary

A Phase 1, Single-center, Open-label, Pharmacokinetic, Safety and Tolerability Study of SB204 in Adolescents with Moderate to Severe Acne Vulgaris

Timeline

Start
2016-06-07
Primary completion
2016-08
Completion
2016-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject BERDAZIMER SODIUM Small molecule 4 % Topical

Indications

acne